Can COVID-19 vaccines improve cardiovascular outcomes?

Thus far, the investigations on the efficacy of the COVID-19 vaccines in randomized trials [8,9] have been centered around reducing the risk of severe infection and mortality. We opine investigations on the efficacy of the COVID-19 vaccines to reduce the risk of cardiovascular outcomes should be performed to understand if COVID-19 vaccination has cardiovascular benefits. Such investigations could also develop more confidence toward the acceptance of COVID-19 vaccines by the public, especially when some of the COVID-19 vaccines (particularly the mRNA vaccines such as BNT162b2 and mRNA-1273 vaccines) have been associated with the rare occurrence of cardiovascular complications, including myocarditis and pericarditis [10,11]. While the infrequency and the mild nature of the myocarditis and pericarditis cases after vaccination greatly exceed the small increased risk, specious reports on social media are still fueling the COVID-19 vaccine hesitancy. Therefore, we urge the performance of prospective investigations to establish the relationship between COVID-19 vaccines and cardiovascular outcomes.